The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs

Christine Sekaggya-Wiltshire, Mohammed Lamorde, Agnes N. Kiragga, Kelly E. Dooley, Moses R. Kamya, Andrew Kambugu, Jan Fehr, Yukari C. Manabe, Barbara Castelnuovo

Research output: Contribution to journalReview articlepeer-review

Abstract

Tuberculosis (TB) is a major public health problem. Many countries still fall below the minimum World Health Organization (WHO) TB treatment target success rate. There is conflicting evidence about whether concentrations of anti-tuberculosis drugs given at standard doses have an effect on treatment outcomes. The current data correlating anti-TB drug concentrations and treatment outcome is limited. This article summarized the existing literature and their utility in evaluating the association between each anti-TB drug's concentrations using current target concentrations and treatment outcomes in patients with pulmonary tuberculosis receiving standard WHO-recommended dosing.

Original languageEnglish (US)
Pages (from-to)77-82
Number of pages6
JournalTuberculosis
Volume108
DOIs
StatePublished - Jan 2018

Keywords

  • Anti-tuberculosis drugs
  • Concentrations
  • Treatment outcomes

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs'. Together they form a unique fingerprint.

Cite this